Physician profile
John F Smith
NPI 1023085719
$1,389.96
in general payments reported to CMS, 2019-2025
19 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $211 · 2021: $82.16 · 2022: $48.98 · 2023: $547 · 2024: $251 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,048.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $426.82 | 2020-2025 | Rinvoq, Skyrizi, Linzess |
| Shockwave Medical, INC | $168.42 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.11 | 2020-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.09 | 2023-2024 | Trulance |
| E.R. Squibb & Sons, L.L.C. | $82.16 | 2021 | |
| Intercept Pharmaceuticals, INC. | $81.50 | 2023-2024 | Ocaliva |
| Ardelyx, INC. | $52.69 | 2024-2025 | Ibsrela |
| Janssen Biotech, INC. | $39.11 | 2023 | Stelara, Simponi, Simponi Aria |
| Mylan Institutional INC. | $38.69 | 2023 | Hulio |
| Braintree Laboratories, INC. | $38.24 | 2023 | Sutab, Suflave |
| Lilly USA, LLC | $36.76 | 2024 | Omvoh |
| Nestle Healthcare Nutrition INC. | $34.93 | 2023 | |
| Ferring Pharmaceuticals INC. | $33.87 | 2023-2024 | Rebyota, Clenpiq |
| Regeneron Healthcare Solutions, INC. | $24.77 | 2023 | Dupixent |
| Amgen INC. | $22.82 | 2023 | Amjevita |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $22.77 | 2024 | Sucraid |
| Merck Sharp & Dohme LLC | $22.12 | 2022 | |
| Ironwood Pharmaceuticals, INC | $17.34 | 2023 | Linzess |
| Celgene Corporation | $13.75 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.